Events & Resources
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More →Topics
See All Topics →Latest Articles
Explore our Research →Search engines reign, but social has standing in Latin America
Article |
Jul 14, 2025
Timing, targeting, and transformation: Inside Every Man Jack’s full-funnel strategy
Article |
Jul 14, 2025
Why commerce media networks have grown so quickly
Article |
Jul 14, 2025
Levi Strauss streamlines product assortment to maximize profits amid uncertainty
Article |
Jul 14, 2025
Google acqui-hires Windsurf to boost AI coding amid tech talent war
Article |
Jul 14, 2025
CTAs lead the way in email engagement tactics
Article |
Jul 11, 2025
SNAP cuts in Trump’s “big, beautiful bill” could shake up grocery
Article |
Jul 11, 2025
Marketers stick with TikTok Shop despite its uncertain future
Article |
Jul 11, 2025
Faster drug approvals are possible with global price concessions, FDA chief says
Article |
Jul 11, 2025
T-Mobile extends Starlink to rivals, creating ad paths beyond cell towers
Article |
Jul 11, 2025
About
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More →Already have a subscription?Sign In
Access All Charts and Data
Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.
Access All Charts and Data
Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.
October 19, 2021
US Payers and Employers Who View Prescription Digital Therapeutics (PDTs) as an Effective Tool for Treating Unmet Needs in Select Diseases, Summer 2021 (% of respondents in each group)
Note
Respondents were asked, "Do you view PDTs as an effective tool for treating unmet needs in the diseases areas below? Please select all that apply."Methodology
Data is from the October 2021 Pear Therapeutics and Avalere report titled "Pear Prescription Digital Therapeutics (PDT) Digest." 40 US payers (n=30) and employers (n=10), who are familiar with PDT, were surveyed during summer 2021. 75% of the respondents was payer or pharmacy benefit managers, and 25% was employer or employer benefits consultants who represented employer self-insured groups. The payer respondents collectively represented 192 million covered lives.Featured In
The Rise of Digital TherapeuticsMost Medicare Advantage plans fall short on abuse disorder coverageEmployers’ high healthcare spending opens a big opportunity for prescription digital therapeutics US employers combat high heart health costs with digital therapiesWisconsin residents get easier access to digital therapies for addiction management FDA clears H2o Therapeutics’ app for Parkinson’s DiseaseChart Title
US Payers and Employers Who View Prescription Digital Therapeutics (PDTs) as an Effective Tool for Treating Unmet Needs in Select Diseases, Summer 2021 (% of respondents in each group)Publication Date
October 19, 2021
